AstraZeneca plc Receives “Underweight” Rating from JPMorgan Chase & Co. (AZN)
AstraZeneca plc (NYSE:AZN) opened at 76.31 on Thursday. AstraZeneca plc has a 52 week low of $47.51 and a 52 week high of $82.68. The stock’s 50-day moving average is $74.07 and its 200-day moving average is $67.81. The company has a market cap of $96.227 billion and a price-to-earnings ratio of 45.86.
AstraZeneca plc (NYSE:AZN) last released its earnings data on Thursday, April 24th. The company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter in the previous year, the company posted $1.41 earnings per share. The company’s revenue for the quarter was up .5% on a year-over-year basis. On average, analysts predict that AstraZeneca plc will post $4.23 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on AZN. Analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. Separately, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, June 20th. Finally, analysts at Citigroup Inc. reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, June 20th. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $58.67.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.